Niels Steen Krogh Selected Research

Rheumatoid Arthritis

1/2023	Remission, response, retention and persistence to treatment with disease-modifying agents in patients with rheumatoid arthritis: a study of harmonised Swedish, Danish and Norwegian cohorts.
12/2022	Flare during tapering of biological DMARDs in patients with rheumatoid arthritis in routine care: characteristics and predictors.
11/2022	Infliximab biosimilar-to-biosimilar switching in patients with inflammatory rheumatic disease: clinical outcomes in real-world patients from the DANBIO registry.
1/2022	Prospective Studies on the Risk of Rheumatoid Arthritis: The European Risk RA Registry.
11/2021	Comparative effectiveness of two adalimumab biosimilars in 1318 real-world patients with inflammatory rheumatic disease mandated to switch from originator adalimumab: nationwide observational study emulating a randomised clinical trial.
1/2021	Self-protection strategies and health behaviour in patients with inflammatory rheumatic diseases during the COVID-19 pandemic: results and predictors in more than 12 000 patients with inflammatory rheumatic diseases followed in the Danish DANBIO registry.
1/2019	To switch or not to switch: results of a nationwide guideline of mandatory switching from originator to biosimilar etanercept. One-year treatment outcomes in 2061 patients with inflammatory arthritis from the DANBIO registry.
1/2019	Risk of serious infections in patients with rheumatoid arthritis treated in routine care with abatacept, rituximab and tocilizumab in Denmark and Sweden.
1/2019	Efficacy and safety of cannabidiol followed by an open label add-on of tetrahydrocannabinol for the treatment of chronic pain in patients with rheumatoid arthritis or ankylosing spondylitis: protocol for a multicentre, randomised, placebo-controlled study.
8/2017	A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registry.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Niels Steen Krogh Research Topics

Disease

15	Psoriatic Arthritis 04/2024 - 02/2011
14	Rheumatoid Arthritis 01/2023 - 07/2011
11	Axial Spondyloarthritis 10/2023 - 10/2015
6	Ankylosing Spondylitis 09/2023 - 11/2010
5	Necrosis 01/2023 - 11/2010
5	Rheumatic Diseases (Rheumatism) 11/2022 - 07/2011
5	Pain (Aches) 01/2019 - 05/2013
3	Neoplasms (Cancer) 12/2023 - 01/2018
3	Fatigue 01/2019 - 05/2013
2	Dermatitis 12/2023 - 05/2023
2	Arthritis (Polyarthritis) 11/2022 - 08/2017
2	Joint Diseases (Joint Disease) 01/2020 - 01/2020
1	Dermatomyositis (Dermatopolymyositis) 12/2023
1	Conjunctivitis 05/2023
1	Atopic Dermatitis (Atopic Eczema) 05/2023
1	Synovitis 12/2022
1	Human Influenza (Influenza) 10/2022
1	COVID-19 01/2021
1	Nausea 01/2020
1	Vomiting 01/2020
1	Infections 01/2019
1	Chronic Pain 01/2019
1	Deglutition Disorders (Dysphagia) 01/2018
1	Interstitial Lung Diseases (Interstitial Lung Disease) 01/2018
1	Inclusion Body Myositis 01/2018
1	Body Weight (Weight, Body) 11/2014

Drug/Important Bio-Agent (IBA)

8	Tumor Necrosis Factor InhibitorsIBA 04/2024 - 01/2013
7	C-Reactive ProteinIBA 09/2023 - 11/2010
5	Antirheumatic Agents (DMARD)IBA 01/2023 - 01/2013
5	Biosimilar PharmaceuticalsIBA 11/2022 - 08/2017
5	Infliximab (Remicade)FDA Link 11/2022 - 11/2014
4	ametantrone (HAQ)IBA 10/2022 - 05/2013
4	Etanercept (Enbrel)FDA Link 01/2020 - 01/2018
3	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 12/2014 - 02/2011
2	AutoantibodiesIBA 12/2023 - 01/2022
2	Rituximab (Mabthera)FDA Link 01/2023 - 01/2019
2	ORALIT (ORS)IBA 01/2022 - 01/2021
2	secukinumabIBA 01/2022 - 01/2021
2	Adalimumab (Humira)FDA Link 11/2021 - 01/2018
2	amsonic acid (DAS)IBA 01/2020 - 01/2018
2	tocilizumab (atlizumab)FDA Link 01/2019 - 07/2011
2	Abatacept (Orencia)FDA Link 01/2019 - 07/2011
1	Ligases (Synthetase)IBA 12/2023
1	dupilumabIBA 05/2023
1	Methotrexate (Mexate)FDA LinkGeneric 01/2023
1	Rheumatoid FactorIBA 12/2022
1	GP1111IBA 11/2022
1	COVID-19 VaccinesIBA 10/2022
1	Anti-Citrullinated Protein AntibodiesIBA 01/2022
1	AntibodiesIBA 12/2021
1	GP2017IBA 11/2021
1	Dronabinol (THC)FDA LinkGeneric 01/2019
1	Medical MarijuanaIBA 01/2019
1	CannabidiolIBA 01/2019
1	CT-P13IBA 08/2017
1	Prostaglandins AIBA 10/2015

Therapy/Procedure

5	Therapeutics 10/2023 - 02/2011
1	Precision Medicine 01/2023
1	Drug Therapy (Chemotherapy) 01/2020
1	Drug Substitution 12/2014
1	Duration of Therapy 11/2010